Literature DB >> 28265683

[Recurrent thromboembolisms despite full anticoagulation in a patient with antiphospholipid syndrome].

S Wernicke1, K Selleng2, S B Felix3, A Greinacher2, F Hammer3.   

Abstract

We report on a female patient with confirmed secondary antiphospholipid syndrome (APS) due to underlying systemic lupus erythematosus (SLE). Despite a thromboplastin time within the normal range (international normalized ratio, INR) under treatment with a vitamin K antagonist (VKA), a recurrent thrombotic event occurred, this time as pulmonary embolism due to bilateral deep vein thrombosis. Despite an INR value in the therapeutic range, clotting factors II, VII, IX and X were found to be insufficiently decreased suggesting inefficient anticoagulation. Thus, the anticoagulation regimen was changed to the direct oral anticoagulant dabigatran. This case demonstrates that the INR in APS patients may be artificially prolonged in rare cases, despite a normal activated partial thromboplastin time (aPTT) and cannot be used for monitoring VKA anticoagulant therapy. Suspicion of ineffective anticoagulation despite VKA therapy should prompt measurement of the individual clotting factors.

Entities:  

Keywords:  Lupus erythematosus, systemic; Partial thromboplastin time; Pulmonary embolism; Venous thromboembolism; Vitamin K antagonists

Mesh:

Substances:

Year:  2017        PMID: 28265683     DOI: 10.1007/s00108-017-0211-6

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  9 in total

1.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

2.  Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodies.

Authors:  Stephanie L Perry; Gregory P Samsa; Thomas L Ortel
Journal:  Thromb Haemost       Date:  2005-12       Impact factor: 5.249

3.  Warfarin and the antiphospholipid syndrome: does one size fit all?

Authors:  Raj S Kasthuri; Robert A S Roubey
Journal:  Arthritis Rheum       Date:  2007-12-15

4.  A randomized clinical trial of high-intensity warfarin vs. conventional antithrombotic therapy for the prevention of recurrent thrombosis in patients with the antiphospholipid syndrome (WAPS).

Authors:  G Finazzi; R Marchioli; V Brancaccio; P Schinco; F Wisloff; J Musial; F Baudo; M Berrettini; S Testa; A D'Angelo; G Tognoni; T Barbui
Journal:  J Thromb Haemost       Date:  2005-05       Impact factor: 5.824

Review 5.  Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

6.  Dabigatran versus warfarin in the treatment of acute venous thromboembolism.

Authors:  Sam Schulman; Clive Kearon; Ajay K Kakkar; Patrick Mismetti; Sebastian Schellong; Henry Eriksson; David Baanstra; Janet Schnee; Samuel Z Goldhaber
Journal:  N Engl J Med       Date:  2009-12-10       Impact factor: 91.245

Review 7.  Prophylaxis of the antiphospholipid syndrome: a consensus report.

Authors:  D Alarcón-Segovia; M C Boffa; W Branch; R Cervera; A Gharavi; M Khamashta; Y Shoenfeld; W Wilson; R Roubey
Journal:  Lupus       Date:  2003       Impact factor: 2.911

8.  The management of thrombosis in the antiphospholipid-antibody syndrome.

Authors:  M A Khamashta; M J Cuadrado; F Mujic; N A Taub; B J Hunt; G R Hughes
Journal:  N Engl J Med       Date:  1995-04-13       Impact factor: 91.245

9.  Rivaroxaban in antiphospholipid syndrome (RAPS) protocol: a prospective, randomized controlled phase II/III clinical trial of rivaroxaban versus warfarin in patients with thrombotic antiphospholipid syndrome, with or without SLE.

Authors:  H Cohen; C J Doré; S Clawson; B J Hunt; D Isenberg; M Khamashta; N Muirhead
Journal:  Lupus       Date:  2015-05-04       Impact factor: 2.911

  9 in total
  1 in total

1.  [Decompensated heart failure as a result of a systemic disease].

Authors:  B Greiner; K Remde; H-M Lorenz; R Max
Journal:  Med Klin Intensivmed Notfmed       Date:  2019-04-11       Impact factor: 0.840

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.